Treatment of cutaneous leishmaniasis recidivans with a combination of allopurinol and meglumine antimoniate: A clinical and histologic study

International Journal of Dermatology

Volumn 46, Issue 8, 2007, Pages 848-852

  Esfandiarpour, Iraj ^a   Dabiri, Shahriar H ^a  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CREATININE; MEGLUMINE ANTIMONATE; NITROGEN; RIFAMPICIN; STIBOGLUCONATE SODIUM; UREA;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CRYOTHERAPY; DISEASE COURSE; DISEASE DURATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HISTIOCYTE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY FUNCTION TEST; LEISHMANIASIS RECIDIVANS; LIVER FUNCTION TEST; LYMPHOCYTIC INFILTRATION; MALE; OPEN STUDY; RECURRENT INFECTION; SIDE EFFECT; SKIN BIOPSY; SKIN DEFECT; SKIN FIBROSIS; SKIN GRANULOMA; SKIN LEISHMANIASIS; SMEAR; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL;

ADOLESCENT; ADULT; ALLOPURINOL; ANIMALS; ANTIMETABOLITES; ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FACE; FEMALE; HUMANS; LEISHMANIASIS, CUTANEOUS; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; RECURRENCE; TREATMENT OUTCOME;

EID: 34547455815     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2007.03086.x     Document Type: Article

References (31)

1. World Health Organization. Control of Leishmaniasis. Report of a WHO Expert Committee. Technical Report Series 793. Geneva: World Health Organization, 1990: 52-54.
2. Nadim A, Mesghali A, Amini H. Epidemiology of cutaneous leishmaniasis in Isfahan, Iran, Part III. The vector. Trans R Soc Trop Med Hyg 1971; 62: 543-548.
3. Nadim A, Seyedi-Rashti MA. Brief review of the epidemiology of various types of leishmaniasis in Iran. Acta Med Iran 1971; 14: 99-106.
4. Sharifi I, Fekri AR, Aflatonian A et al. Cutaneous leishmaniasis in primary school children in the Southeastern Iranian city of Bam, 1994-95. Bull World Health Organization 1998; 76: 289-293.
5. Dowlaty Y. Cutaneous leishmaniasis. Int J Dermatol 1979; 18: 362-368.
6. Momeni AR, Aminijavaheri M. Treatment of recurrent cutaneous leishmaniasis. Int J Dermatol 1995; 34: 129-132.
7. Olveira DA Jr, Roberto P, Machado L, et al. Evaluating the efficacy of allopurinol for treatment of cutaneous leishmaniasis. Int J Dermatol 1997; 36: 938-940.
8. Valez ID, Argudelo S, Grog M, et al. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. Acta Parasitol Turcica 1997; 21: 186.
9. Martinez S, Marr JJ. Allopurinol in the treatment of American cutaneous leishmaniasis. N Engl J Med 1992; 326: 741-744.
10. Momeni AR, Aminjavaheri M. Successful treatment of non-healing cases of cutaneous leishmaniasis using a combination of meglumine antimoniate plus allopurinol. Eur J Dermatol 2003; 13: 40-43.
11. Esfandiarpour I, Alavi A. Evaluation of the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. Int J Dermatol 2002; 41: 521-524.
12. Momeni AR, Yotsumoto S, Mehregan D, et al. Chronic lupoid leishmaniasis. Arch Dermatol 1996; 132: 198-202.
13. Grevelink SA, Lcrner EA. Leishmaniasis. J Am Acad Dermatol 1996; 34: 257-272.
14. Mavilia L, Rossi R, Massi D, et al. Leishmaniasis recidival cutis: An unusual two-step recurrence. Int J Dermatol 2002; 41: 506-507.
15. Koff AB, Rosen T. Treatment of cutaneous leishmaniasis. J Am Acad Dermatol 1994; 31: 693-708.
16. Grogl M, Thomason TN, Frune ED. Drug resistance in leishmaniasis: Its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. Am J Trop Med Hyg 1992; 47: 117-126.
17. Olliaro PL, Bryceson ADM. Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol Today 1993; 9: 323-328.
18. Chunge CN, Gachihi G, Muigai R, et al. Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol. Trans R Soc Trop Med Hyg 1985; 79: 715-718.
19. Jha TK. Evaluation of allopurinol in the treatment of kala azar occurring in North Bihar, India. Trans R Soc Trop Med Hyg 1983; 77: 204-207.
20. Kager PA, Rees TH, Wellde BT, et al. Allopurinol in the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 1981; 75: 556-559.
21. Marr JJ, Berens RL. Purine metabolism in leishmania. In: Chang KP, Bray RS, eds. Human Parasitic Disease, Vol. 1, Leishmaniasis. Amsterdam: Elsevier, 1985: 69-78.
22. Looker DL, Berens RL, Marr JJ. Purine metabolism in Leishmania donovani amastigotes and promastigotes. Mol Biochem Parasitol 1983; 9: 15-28.
23. Marr JJ, Berens RL. Pyrazolopyrimidine metabolism in the pathogenic trypanosomatidae. Mol Biochem Parasitol 1983; 7: 339-356.
24. Berens RL, Marr JJ, Nelson DJ, et al. Antileishmanial effect of allopurinol and allopurinol ribonucleoside on intracellular forms of Leishmania donovani. Biochem Pharmacol 1980; 29: 2397-2398.
25. Marr JJ, Berens RL, Nelson DJ, et al. Antileishmanial action of 4-thiopyrazolo(3,4-D)pyrimidine and its ribonucleoside. Biochem Pharmacol 1982; 31: 143-148.
26. Lafon SW, Nelson DJ, Berens RL, et al. Inosine analogs: Their metabolism in mouse cells and in Leishmania donovani. J Biol Chem 1985; 260: 9660-9665.
27. Martinez S, Looker DL, Berens RL, et al. The synergistic action of pyrazolopyrimidines and pentavalent antimony against Leishmania donovani and L. braziliensis. Am J Trop Med Hyg 1988; 39: 250-255.
28. 1 activity is associated with severe infections. Clin Exp Immunol 1995; 100: 239-245.
29. 1 -like response to Leishmania major promastigote antigens in individuals recovered from cutaneous leishmaniasis. Clin Exp Immunol 1994; 96: 410-415.
30. Ajdary S, Alimohammadian MH, Eslami MB, et al. Comparison of the immune profile of nonhealing cutaneous leishmaniasis patients with those with active lesions and those who have recovered from infection. Infect Immun 2000; 68: 1760-1764.
31. Schonlau F, Schlesigen C, Ehrchen J, et al. Monocyte and macrophage functions in M-CSF-deficient op/op mice during experimental leishmaniasis. J Leuk Biol 2003; 73: 564-573.